Literature DB >> 28864556

Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab.

Barathy Rani Ramasamy1, Patrick Charles1,2, Douglas Johnson1,2, Albert Frauman3,4.   

Abstract

A 32-year-old man who was receiving adalimumab for seronegative rheumatoid arthritis presented with a 4-week history of fever, night sweats, fatigue, myalgias and diarrhoea. On examination, he had obvious splenomegaly but no lymphadenopathy or pharyngitis. Full blood count revealed mild neutropenia and significant lymphocytosis, with a blood film showing atypical lymphocytes. Liver function tests were mildly deranged with a mixed hepatitic and obstructive pattern. Ultrasound confirmed massive splenomegaly with a span of 21 cm in the long axis. Serological tests confirmed the presence of both primary Epstein-Barr virus and cytomegalovirus infections. The patient had his adalimumab withheld, was treated with supportive measures and improved over a period of 8 weeks. He remained well 5 months after the onset of illness with complete normalisation of blood count and a resolution of the splenomegaly. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Infectious diseases; rheumatoid arthritis; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2017        PMID: 28864556      PMCID: PMC5589034          DOI: 10.1136/bcr-2017-220184

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  27 in total

Review 1.  Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus?

Authors:  G Starkebaum
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

Review 2.  Epstein-Barr virus-recent advances.

Authors:  Karen F Macsween; Dorothy H Crawford
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

Review 3.  Diagnosis of Epstein-Barr virus-associated diseases.

Authors:  Shigeru Tsuchiya
Journal:  Crit Rev Oncol Hematol       Date:  2002-12       Impact factor: 6.312

4.  Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy.

Authors:  Daniel Helbling; Thomas H Breitbach; Martin Krause
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 2.566

5.  Clinical and laboratory findings of cytomegalovirus infection in 115 hospitalized non-immunocompromised adults.

Authors:  F Bonnet; D Neau; J F Viallard; P Morlat; J M Ragnaud; M Dupon; P Legendre; Y Imbert; F Lifermann; M Le Bras; J Beylot; M Longy-Boursier
Journal:  Ann Med Interne (Paris)       Date:  2001-06

6.  Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis.

Authors:  Georg Haerter; Burkhard J Manfras; Yvonne de Jong-Hesse; Heike Wilts; Thomas Mertens; Peter Kern; Michael Schmitt
Journal:  Clin Infect Dis       Date:  2004-10-11       Impact factor: 9.079

7.  Massive splenomegaly and Epstein-Barr virus-associated infectious mononucleosis in a patient with Gaucher disease.

Authors:  M Eapen; M Hostetter; J P Neglia
Journal:  J Pediatr Hematol Oncol       Date:  1999 Jan-Feb       Impact factor: 1.289

8.  Significant liver injury with dual positive IgM antibody to Epstein-Barr virus and cytomegalovirus as a puzzling initial manifestation of infectious mononucleosis.

Authors:  Takahiro Zenda; Yuji Itoh; Yoshihiro Takayama; Takaharu Masunaga; Satoshi Asaka; Hisanori Oiwake; Kimihide Shinozaki; Ryoyu Takeda
Journal:  Intern Med       Date:  2004-04       Impact factor: 1.271

9.  Infliximab and the risk of latent viruses reactivation in active Crohn's disease.

Authors:  Alessandro Lavagna; Massimiliano Bergallo; Marco Daperno; Raffaello Sostegni; Cristina Costa; Rosalia Leto; Lucia Crocellà; Giancarlo Molinaro; Rodolfo Rocca; Rossana Cavallo; Angelo Pera
Journal:  Inflamm Bowel Dis       Date:  2007-07       Impact factor: 5.325

Review 10.  Pathogenesis of haemophagocytic lymphohistiocytosis.

Authors:  M Aricò; C Danesino; D Pende; L Moretta
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

View more
  1 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.